Abstract 99P
Background
Generally, cancer cell lines are established from the patients of which cancer cells are dissected, cultured and maintained in vitro. These cell lines have been traditionally used in cancer research; however, they have changed better to survive in culture condition in vitro, and not restored the original characters when they grew in vivo, meaning the lack of tumor heterogeneity. Primary culture of cancer cells derived from patients’ tumors can provide crucial information as each “individual tumor”. The primary culture method of clinical cancer and the evaluation for the treatment have not been clearly optimized in gastrointestinal cancers.
Methods
We have developed a simple 2D/3D-culture method for primary cancer. We obtained 40 clinical samples from surgically resected colorectal cancers (CRCs). They were mechanically and enzymatically digested and are filtered by customized preparation tools, followed by in vitro culture system. The gene expression profiles and the sensitivity for the drugs were analyzed.
Results
Culture cells were analyzed These cultured cancer cells were named “isolated-tumor derived Cancer Cells (iCCs).” All iCCs grew and about 90 % of iCCs were successfully passaged. These iCCs were transplanted into the subcutaneous tissue of nonobese diabetic (NOD) - severely compromised immune deficient (SCID) mice, and the tumor growth and pathological examination were evaluated. The morphology was similar to each parental clinical tumor. Microarray analyses showed that RNA expression of iCCs was similar to each parental tumor. Surface markers regarding cancer stem cells expressed in iCCs. Furthermore, multi-drug sensitivity assay by our bespoke plates including commonly used as anti-cancer/molecular target drugs was performed.
Conclusions
The iCCs are very similar to each parental tumor, leading to the personalized medicine, and the analyses of the tumor characteristics seem to reflect the clinical presentation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Japanese Agency for Medical Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
Presenter: Kristina Havrysh
Session: Poster display session
Resources:
Abstract
383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Presenter: Yonggang Peng
Session: Poster display session
Resources:
Abstract
384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
Presenter: Min Kyu Kim
Session: Poster display session
Resources:
Abstract
385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
Presenter: Alireza Pasdar
Session: Poster display session
Resources:
Abstract
386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation
Presenter: Leysan Minigulova
Session: Poster display session
Resources:
Abstract
387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
Presenter: Jee hyun Ahn
Session: Poster display session
Resources:
Abstract
388P - To identify circulating tumour cells by machine learning approach
Presenter: Yuebin Liang
Session: Poster display session
Resources:
Abstract
389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Presenter: Jing-Hua Chen
Session: Poster display session
Resources:
Abstract
395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019
Presenter: Lance Isidore Catedral
Session: Poster display session
Resources:
Abstract
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract